Our Pricing

Mounjaro vs Ozempic UK: Clinical Comparison for Weight Loss

When considering a mounjaro vs ozempic uk comparison, understanding the clinical differences between these two prescription treatments is essential for making an informed decision. Both medications have transformed weight management in the UK, but they work through different mechanisms and deliver distinct results in clinical trials. At Cured Pharmacy, our UK-registered clinical team helps patients navigate these options through comprehensive online consultations, with Mounjaro available from £135.00 following prescriber approval.

Understanding Mounjaro vs Ozempic: The Fundamental Difference

Mounjaro (tirzepatide) and Ozempic (semaglutide) belong to different medication classes, despite both being weekly injections for weight management. Mounjaro is the first dual GIP/GLP-1 receptor agonist licensed by the MHRA, activating two incretin hormone pathways simultaneously [1]. Ozempic, conversely, is a single GLP-1 receptor agonist that targets only one pathway.

This dual-action mechanism in Mounjaro produces notably different clinical outcomes. In head-to-head comparisons, tirzepatide demonstrated superior weight reduction compared to semaglutide across multiple doses [2]. The SURPASS-2 trial showed patients on Mounjaro 15mg achieved an average 24.2% body weight reduction over 72 weeks, compared to 16.8% with semaglutide 1mg [2].

Both medications work by slowing gastric emptying, reducing appetite, and improving blood sugar regulation. However, the additional GIP receptor activation in Mounjaro appears to enhance fat metabolism and insulin sensitivity beyond what GLP-1 activation alone achieves [1]. This doesn't mean Mounjaro is universally superior—individual response varies, and your UK prescriber will assess which treatment suits your medical profile.

Clinical Efficacy: What the Trial Data Shows

The SURPASS clinical trial programme evaluated tirzepatide across multiple studies involving over 10,000 participants. In SURPASS-3, patients receiving the highest Mounjaro dose achieved an average 22.5% body weight reduction over 72 weeks [2]. The STEP trials for semaglutide demonstrated an average 14.9% weight reduction at 68 weeks with the 2.4mg dose used in Wegovy [3].

It's crucial to understand these are average results from controlled clinical trials. Individual outcomes vary significantly based on adherence, lifestyle modifications, baseline weight, and metabolic factors. Some patients respond exceptionally well to semaglutide-based treatments, whilst others achieve better results with tirzepatide.

Both medications require commitment to dietary changes and increased physical activity for optimal results. The MHRA licensing for both treatments specifies they should be used alongside a reduced-calorie diet and increased physical activity [4]. Neither medication is a standalone solution—they're tools that work best when integrated into a comprehensive weight management programme.

Real-World Effectiveness Beyond Trials

Clinical trial conditions differ from real-world use. Patients in trials receive intensive support, regular monitoring, and structured lifestyle interventions. In everyday practice, results may vary. Our clinical team at Cured Pharmacy provides ongoing support to help optimise your treatment outcomes, regardless of which medication your prescriber recommends.

Dosing Schedules and Administration

Both Mounjaro and Ozempic are administered as once-weekly subcutaneous injections, typically in the abdomen, thigh, or upper arm. Mounjaro uses a dose-escalation schedule starting at 2.5mg weekly, increasing every four weeks to 5mg, 7.5mg, 10mg, 12.5mg, and potentially 15mg based on individual tolerance and response [1].

Ozempic follows a different escalation pattern, starting at 0.25mg weekly for four weeks, then 0.5mg, with potential increases to 1mg or 2mg for enhanced glycaemic control. For weight management specifically, the higher-dose semaglutide formulation (Wegovy) is typically preferred, reaching up to 2.4mg weekly [3].

The gradual dose increases for both medications help minimise gastrointestinal side effects, which are the most common adverse events reported. Your UK prescriber determines your starting dose and escalation schedule based on your medical history, current medications, and individual tolerability. Never adjust your prescribed dose without consulting your healthcare provider.

Side Effect Profiles: What to Expect

Both medications share similar side effect profiles, predominantly affecting the gastrointestinal system. The most frequently reported adverse events include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort [1][3]. These effects are typically most pronounced during dose escalation and often diminish with continued use.

In clinical trials, approximately 44% of Mounjaro patients experienced nausea, compared to 44% with semaglutide at comparable efficacy doses [2]. The incidence of gastrointestinal side effects correlates with dose—higher doses generally produce more frequent symptoms, though individual variation is substantial.

Serious but rare side effects for both medications include pancreatitis, gallbladder disease, and potential thyroid tumours (observed in rodent studies, not confirmed in humans). Both carry contraindications for patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [4]. Your UK prescriber will screen for these conditions during your clinical assessment.

Managing Common Side Effects

Most patients find gastrointestinal symptoms manageable with dietary adjustments. Eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and eating slowly can significantly reduce nausea and discomfort. If side effects become intolerable, your prescriber may adjust your dose escalation schedule or consider alternative treatments available through Cured Pharmacy.

Cost Considerations and UK Availability

Mounjaro is available at Cured Pharmacy from £135.00 per month, subject to clinical assessment and prescriber approval. Pricing reflects the prescribed dose, with higher-dose pens typically costing more. We maintain transparent upfront pricing—you'll see exact costs before completing your consultation.

Both medications require prescription from a UK-registered prescriber. At Cured Pharmacy, our online consultation takes under three minutes and is reviewed by qualified UK clinicians. We never charge consultation fees—you only pay for medication if deemed clinically appropriate. All treatments are dispensed as genuine UK-licensed medicines from our GPhC-registered pharmacy.

Supply availability can fluctuate for both medications due to high demand across the UK. We maintain updated stock information and can advise on alternative treatments if your preferred option is temporarily unavailable. Our clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), ensures continuity of care regardless of supply challenges.

Making Your Decision: Mounjaro vs Ozempic UK

Choosing between Mounjaro and Ozempic isn't about selecting the 'better' medication—it's about identifying which treatment aligns with your individual medical profile, weight loss goals, and tolerance for potential side effects. Clinical trial data suggests tirzepatide may produce greater average weight reduction, but individual response varies considerably [2][3].

Your UK prescriber will consider multiple factors: your BMI, weight loss goals, medical history, current medications, previous treatment responses, and any contraindications. Patients with certain cardiovascular conditions, gastrointestinal disorders, or medication interactions may be better suited to one treatment over another.

At Cured Pharmacy, we offer comprehensive weight management options beyond Mounjaro and Ozempic. Wegovy (the higher-dose semaglutide formulation specifically licensed for weight management) provides another GLP-1 option, whilst Saxenda offers a daily injection alternative for patients preferring more frequent, lower-dose administration. For those unsuitable for injectable treatments, oral options like Orlistat provide fat-absorption blocking mechanisms.

Starting Your Weight Loss Journey

Beginning treatment requires realistic expectations and commitment to lifestyle changes. These medications are powerful tools, but they work best when combined with dietary modifications, increased physical activity, and behavioural changes. Our clinical team provides ongoing support throughout your treatment journey, with regular medication reviews and dose adjustments as needed. Start your free online consultation today to discover which treatment option suits your needs.

Scientific References

1. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): A Randomised, Open-Label, Phase 3 Trial. The Lancet, 398(10295), 64–77. https://doi.org/10.1016/S0140-6736(21)01324-6
3. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
4. Medicines and Healthcare products Regulatory Agency. (2023). Public Assessment Report: Mounjaro 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg solution for injection in pre-filled pen. GOV.UK.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment, dietary modifications, and physical activity levels.